Physician profile
Marcus J Smith
NPI 1578769055
$67,295.17
in general payments reported to CMS, 2019-2025
45 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $7,576 · 2021: $2,563 · 2022: $1,367 · 2023: $1,136 · 2024: $1,237 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37,965.79 | 2019-2021 | |
| Lilly USA, LLC | $19,424.91 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,818.11 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,279.89 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $725.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $662.57 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $596.07 | 2019-2024 | Cardiomems, Mitraclip |
| Amgen INC. | $483.60 | 2019-2025 | Repatha |
| Novo Nordisk INC | $466.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $399.94 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $373.75 | 2021-2023 | Verquvo |
| Esperion Therapeutics, INC. | $353.63 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $253.20 | 2019-2023 | |
| Terumo Medical Corporation | $250.00 | 2020 | |
| Astellas Pharma US INC | $201.44 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $189.06 | 2019-2025 | |
| Philips North America LLC | $188.08 | 2019-2021 | |
| Boston Scientific Corporation | $184.34 | 2019-2025 | Wallstent Rp Endoprosthesis |
| Cvrx, INC. | $175.27 | 2021-2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $162.32 | 2022-2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $150.10 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $124.55 | 2021 | |
| Pfizer INC. | $119.37 | 2019-2024 | |
| Medtronic, INC. | $69.75 | 2024 | Symplicity G3 |
| Veryan Medical Incorporated | $68.22 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Actelion Pharmaceuticals US, INC. | $58.26 | 2021-2025 | Opsynvi |
| Baxter Healthcare | $58.17 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Silk Road Medical, INC. | $58.01 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $50.37 | 2023-2024 | Inpefa |
| Lundbeck LLC | $47.12 | 2019 | |
| Medtronic Vascular, INC. | $39.18 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $36.89 | 2019 | |
| Ge Healthcare | $32.67 | 2023 | |
| Irhythm Technologies, INC. | $30.88 | 2020-2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $29.45 | 2019 | |
| Kerecis Limited | $25.21 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Endologix LLC | $23.72 | 2025 | Torus Stent Graft System, Endocross Device |
| Cordis US Corp. | $23.11 | 2024 | Rain Sheath |
| Angiodynamics, INC. | $18.72 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.74 | 2019 | |
| Cardiva Medical, INC. | $15.71 | 2025 | Cardiva Vascade 5f Vcs |
| Zoll Circulation INC | $14.43 | 2021 | |
| Gilead Sciences, INC. | $12.26 | 2019 | |
| Bardy Diagnostics, INC. | $11.25 | 2020 | |
| Althera Pharmaceuticals LLC | $5.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.